play icon video poster

As demand for plasmids and viral vectors outpace capacity, a greater than 10-fold and potentially close to 100-fold increase in manufacturing efficiency for the gene therapy reagents is likely required to meet demand that is increasing exponentially. 

Repligen solutions aim to meet the needs for optimized processes, higher yields, and improved process quality - setting new standards for modern scalable processes from gene to therapy. Repligen also offers hands-on process and implementation consultation led by recognized Gene Therapy, oncolytic and vaccines industry experts.


Speak to an expert

Viral Vectors

Adeno-associated virus (AAV) is the most common viral vector used in gene therapy bioprocessing. Other viral vectors include adenovirus, lentivirus, retrovirus, oncolytic virus, and virus-based vaccines.


Plasmid DNA (pDNA) is a critical raw material delivery template for the development and production of mRNA or viral vectors such as lentivirus and adeno-associated virus (AAV) vectors.


 With the proven success of mRNA-based vaccines in addressing the COVID-19 pandemic, mRNA technology is at the forefront of transforming the world of medicine. Clinical trials are ongoing to develop both vaccines and therapies to treat infectious diseases and even cancer. 

Repligen Cell and Gene Therapy 
​Applications Center

As a thought leader in Gene Therapy bioprocessing, Repligen maintains a state-of-the-art Gene Therapy Applications Center focused on developing internal applications expertise as well as effective collaborations with customers and Gene Therapy leaders.​

The Center is staffed by a team of experts in vaccine and viral vector production, purification and analytics.​

Speak to an expert

Meet the Repligen Experts

Rachel Legmann  

Sr. Director of Technology, Gene Therapy


Rachel Legmann is a subject matter expert focusing on gene therapy processes in upstream, downstream, analytics and scalability areas. She has over 20 years' experience in scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors and proteins for gene therapy.


Contact Rachel

Rene Gantier

Sr. R&D Director, Advanced Bioprocess Applications


René Gantier has 20 years of experience developing production and purification processes for biotherapies. He leads the development of advanced bioprocess applications and technologies with a focus on next-generation cell and gene therapy manufacturing processes.


Contact René